Search Results
Jim Cramer explains why Eli Lilly will be the winner over Biogen in Alzheimer's fight
Jim Cramer on how Lilly's Alzheimer's drug compares to Biogen's
Jim Cramer on how Eli Lilly could be impacted by mixed Alzheimer's drug study results
Eli Lilly CEO discusses FDA's approval of Biogen's new Alzheimer's drug
Eli Lilly CEO on FDA approval pathway for Alzheimer's drugs
Jim Cramer: Eli Lilly stock represents real value
Jim Cramer's first take: Eli Lilly is a 'winner'
Eli Lilly CEO discusses COVID-19 treatments, and Biogen's FDA approval of new Alzheimer's drug
Eli Lilly CEO: Alzheimer's drug trial shows slowed disease progression by 40-60% in early patients
Eli Lilly CEO Ricks on Sales Forecast, Alzheimer's Drug
Opening Remarks & Sponsor Perspective: Eli Lilly | Innovations in Alzheimer’s Research
Why Jim Cramer thinks investors should buy Eli Lilly on the dip
